Holy Grail: Ilumina nabs cancer testing firm in $8B deal September 21, 2020 -- Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing (NGS) technology, data science, and machine learning to identify cancer signals in blood samples.
Genetic testing cut adverse events in heart patients August 27, 2020 -- Personalized genetic testing led to a 34% decrease in the number of patients who had serious adverse events following balloon angioplasties, according to results published August 25 in the Journal of the American Medical Association. Discuss
Thermo Fisher debuts hematology/oncology assays August 19, 2020 -- Thermo Fisher Scientific has debuted hematology/oncology assays that enable simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a day.
FDA approves Guardant's liquid biopsy NGS test August 7, 2020 -- The U.S. Food and Drug Administration (FDA) has approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) to identify patients with specific types of EGFR mutations in a form of metastatic non-small cell lung cancer.
NanoString launches readout technology for NGS August 4, 2020 -- NanoString Technologies has released Cancer Transcriptome Atlas, a new product based on the company's GeoMx digital spatial profiler platform that's optimized for readout on Illumina's next-generation sequencing (NGS) technology.
NIH invests almost $249M in 7 COVID-19 test technologies July 31, 2020 -- The U.S. National Institutes of Health (NIH) is touting the results of its "Shark Tank" approach to spurring development in COVID-19 testing technologies, with $248.7 million invested in a variety of different methods that promise rapid results.